Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation
Brief Summary: RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than observation alone for melanoma.

PURPOSE: This randomized phase III trial is studying vaccine therapy to see how well it works compared to observation alone in treating patients with primary stage II melanoma.


Options:
A: Intervention Type: BIOLOGICAL; Name: GM2-KLH vaccine; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: QS21; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A
B: Arm Label: Ipilimumab 10 mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab10mg/kg | Arm Label: Ipilimumab 3mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab 3mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab10mg/kg; Assigned to Arm(s): Ipilimumab 10 mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab 3mg/kg + HDI; Assigned to Arm(s): Ipilimumab 3mg/kg + HDI
C: Arm Label: Arm I (sargramostim, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim, Biological: Tyrosinase Peptide | Arm Label: Arm II (sargramostim placebo, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Tyrosinase Peptide | Arm Label: Arm III (sargramostim, peptide placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Sargramostim | Arm Label: Arm IV (placebo, peptide placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Arm Label: Arm V (sargramostim); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim | Arm Label: Arm VI (sargramostim placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo), Arm V (sargramostim), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (sargramostim placebo, peptide vaccine), Arm IV (placebo, peptide placebo), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm V (sargramostim) | Intervention Type: BIOLOGICAL; Name: Tyrosinase Peptide; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine)
D: Arm Label: Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Arm Label: Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Corticosteroid: Betamethasone, Drug: Corticosteroid: Dexamethasone, Drug: Corticosteroid: Fludrocortisone, Drug: Corticosteroid: Hydrocortisone, Drug: Corticosteroid: Meprednisone, Drug: Corticosteroid: Methylprednisolone, Drug: Corticosteroid: Prednisolone, Drug: Corticosteroid: Prednisone, Drug: Corticosteroid: Triamcinolone | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients, Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients | Intervention Type: DRUG; Name: Corticosteroid: Betamethasone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Dexamethasone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Fludrocortisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Hydrocortisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Meprednisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Methylprednisolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Prednisolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Prednisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Triamcinolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients

Answer: A